Gilead Sciences (GILD) Interest Coverage Ratio (2009 - 2026)
Gilead Sciences (GILD) reported Interest Coverage Ratio of 10.78 for Q1 2026, up 25.23% on a YoY basis from 8.6 in Q1 2025, and up 38.49% quarter-over-quarter from 7.78 in Q4 2025.
Gilead Sciences (GILD) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Interest Coverage Ratio for 18 years, with the latest figure at 10.78 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 25.23% year-over-year to 10.78; the trailing twelve-month figure through Mar 2026 stood at 10.32 (up 23.52% YoY), and the FY2025 full-year result was 9.79, up 475.33% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 10.78, up from 7.78 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 13.0 in Q3 2025, with the low at 17.02 in Q1 2024.
- Historically, Interest Coverage Ratio has averaged 7.15 across 5 years, with a median of 8.6 in 2025.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio surged 795.59% — and 2024, when it slumped 329.54%.
- Gilead Sciences' Interest Coverage Ratio stood at 10.03 in 2022, then tumbled by 36.23% to 6.4 in 2023, then jumped by 53.94% to 9.85 in 2024, then declined by 20.99% to 7.78 in 2025, then surged by 38.49% to 10.78 in 2026.
- The last three Interest Coverage Ratio figures came in at 10.78 (Q1 2026), 7.78 (Q4 2025), and 13.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -13.73 |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.78 |
| Dec 31, 2025 | 7.78 |
| Sep 30, 2025 | 13.00 |
| Jun 30, 2025 | 9.74 |
| Mar 31, 2025 | 8.60 |
| Dec 31, 2024 | 9.85 |
| Sep 30, 2024 | 3.73 |
| Jun 30, 2024 | 11.16 |
| Mar 31, 2024 | -17.02 |
| Dec 31, 2023 | 6.40 |
| Sep 30, 2023 | 11.31 |
| Jun 30, 2023 | 7.24 |
| Mar 31, 2023 | 7.41 |
| Dec 31, 2022 | 10.03 |
| Sep 30, 2022 | 12.39 |
| Jun 30, 2022 | 8.38 |
| Mar 31, 2022 | 0.83 |
| Dec 31, 2021 | 3.95 |
| Sep 30, 2021 | 15.37 |
| Jun 30, 2021 | 8.77 |